• Molecular NameMethysergide
  • SynonymMethyllysergic acid butanolamide; Methysergid; Methysergidum [INN-Latin]; Metisergide [DCIT]; Metisergido [INN-Spanish]; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide
  • Weight353.466
  • Drugbank_IDDB00247
  • ACS_NO361-37-5
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.4
  • pka6.6
  • LogD (pH=7, predicted)2.16
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.73
  • LogSw (predicted, AB/LogsW2.0)0.17
  • Sw (mg/ml) (predicted, ACD/Labs)0.35
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA57.5
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA prescription drug used for prophylaxis of migraine headaches
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability13.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepaticMethysergide undergoes a high degree of first-pass metabolism, forming methylergometrine
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A